Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer

• Status: Withdrawn
• Trial end date: 2022-02-25
• Target enrollment: 0
• Participant gender: All

Summary

This randomized phase IV trial studies how well the continuous infusion of ropivacaine hydrochloride works in reducing pain after surgery in patients with bladder cancer. Ropivacaine hydrochloride is an anesthetic drug used to decrease pain by numbing an area of the body without putting the patient to sleep. Continuous infusion of ropivacaine hydrochloride may reduce pain and improve the quality of life for patients after bladder surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Southern California
• Collaborator: National Cancer Institute (NCI)
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• Undergoing elective open radical cystectomy

• Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

• Allergy or adverse reaction to ropivacaine (ropivacaine hydrochloride) or any amide type of local anesthesia

• Allergy or adverse reaction to local anesthesia catheter

• Additional surgery at the same time as RC (e.g. nephroureterectomy)

• Coagulopathy

• Thrombocytopenia

• Local or systemic infection

• Pregnancy

• Chronic hepatic disease

• Use of type III antiarrhythmics (e.g. amiodarone)

• History of chronic pain and/or daily opioid use